Jane Goodall to speak next month at the Lyric Baltimore
Dr. Jane Goodall, internationally renowned anthropologist and primatologist, will speak at Lyric Baltimore on March 23 at 3 p.m.
The world's foremost authority on chimpanzees, Goodall has studied apes in the wild in Africa for 65 years, making ground-breaking discoveries, such as their ability to make and use tools, not unlike humans.
At 90, Goodall continues to address audiences around the world — sharing her personal experiences with chimps, championing environmental causes and addressing the perils of climate change. A matriarch of the conservation movement, Goodall has authored more than a dozen eco-friendly books, for adults and children. In 1977, she founded the Jane Goodall Institute, since grown to 25 chapters around the globe. The organization works to inspire younger generations with an awareness of great apes and their needs in the wild.
Tickets for 'An Afternoon with Jane Goodall' can be purchased online at Etix.com or in person at The Lyric Box Office, 140 W. Mount Royal Ave.
Have a news tip? Contact Mike Klingaman at jklingaman@baltsun.com and 410-332-6456.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Delta Collaborates with the Jane Goodall Institute and NMMST to Expand Coral Restoration Education
TAIPEI, June 6, 2025 /PRNewswire/ -- The Delta Electronics Foundation announced a new collaboration with the Jane Goodall Institute and the National Museum of Marine Science and Technology (NMMST) to promote coral restoration education. Using the science picture book 'Saving Our Coral Reefs', published by the Delta Electronics Foundation, as the core teaching material, the program will be introduced into elementary schools across Taiwan as part of their lesson plan structure. Dr. Jane Goodall, the world-renowned ecologist and conservationist, visited Chaojing Coral Conservation Center in Keelung — a joint effort between the Delta Foundation and NMMST. Together with Delta's founder, Mr. Bruce Cheng, she planted her first batch of corals in Taiwan at the facility, showcasing their commitment to marine conservation. Dr. Jane Goodall remarked, ''All ecosystems are intricately connected, from land to sea, from corals to humanity. I'm pleased to see the enterprise in Taiwan actively promoting ocean conservation. Visiting the Chaojing Coral Conservation Center today gave me a fuller understanding of Delta's transnational coral restoration efforts. I hope this collaboration, through the coral picture book and our Roots & Shoots program, will help more people learn about corals and marine conservation." Mr. Bruce Cheng, Delta's founder and Chairman of the Delta Electronics Foundation, said, "Delta has long been committed to energy conservation, decarbonization, and environmental sustainability. In recent years, we have also focused on biodiversity conservation, using Delta's technological strengths to support researchers in coral restoration efforts. Our project has successfully preserved over 40 species of Taiwanese corals and aims to restore 10,000 coral fragments by this summer. We are honored to work with the Jane Goodall Institute and NMMST to use the 'Saving Our Coral Reefs' picture book as a platform to promote awareness and inspire children and the public to care more about Taiwan's oceans—from the perspective of the science behind coral restoration." At the end of 2024, Dr. Jane Goodall was invited to attend the launch event of a coral culture facility as the base for coral restoration at the St. John's Island National Marine Laboratory (SJINML), jointly established by Singapore's National Parks Board (NParks) and the Delta Foundation. This year, the partnership between the Jane Goodall Institute and Delta has further deepened, with the goal of promoting coral and marine ecological awareness through the picture book and Jane Goodall's Roots & Shoots Program. 'Saving Our Coral Reefs' blends real-life photos with illustrations and scientific commentary from experts involved in Delta's coral restoration project. The book provides an approachable and comprehensive way to build readers' knowledge on coral reefs, their ecological roles, and the existential threats they face due to global warming. Through this collaboration, the book will be integrated into NMMST's coral conservation curriculum and the Jane Goodall Institute's school outreach programs, raising public awareness and encouraging broader participation in marine conservation. Looking forward to the future, the three parties plan to continue exploring new models that integrate technology, education, and nature conservation to advance the sustainable development of marine ecosystems. About Delta Delta, founded in 1971, and listed on the Taiwan Stock Exchange (code:2308), is a global leader in switching power supplies and thermal management products with a thriving portfolio of IoT-based smart energy-saving systems and solutions in the fields of industrial automation, building automation, telecom power, data center infrastructure, EV charging, renewable energy, energy storage and display, to nurture the development of smart manufacturing and sustainable cities. As a world-class corporate citizen guided by its mission statement, "To provide innovative, clean and energy-efficient solutions for a better tomorrow," Delta leverages its core competence in high-efficiency power electronics and its ESG-embedded business model to address key environmental issues, such as climate change. Delta serves customers through its sales offices, R&D centers and manufacturing facilities spread over close to 200 locations across 5 continents. Throughout its history, Delta has received various global awards and recognition for its business achievements, innovative technologies and dedication to ESG. Since 2011, Delta has been listed on the Dow Jones Best-in-Class World Index (formerly the DJSI World Index of Dow Jones Sustainability™ Indices) for 14 consecutive years. Delta has also won CDP with double A List for 4 times for its substantial contribution to climate change and water security issues and has been named Supplier Engagement Leader for its continuous development of a sustainable value chain for 7 consecutive years. For detailed information about Delta, please visit: View original content: SOURCE Delta Electronics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
14-04-2025
- Washington Post
The costs of cutting canine testing
Jane Goodall and Marc Bekoff called for a moratorium on federal funding of and an eventual ban on research using dogs in their March 26 Wednesday Opinion essay, 'This is no way to treat a best friend.' Public support for research on companion animals has historically been mixed, but that's probably because of a misunderstanding about research with dogs. Though dogs represent less than 1 percent of animals used in science, their contributions have an outsize impact on human and pet lives. In fact, 18 Nobel laureates worked with dogs for their research. The field of human and canine comparative oncology, in which researchers study the similarities of cancers in humans and pets, is in its infancy. Many cancers present in similar ways in dogs and humans, including bone, prostate, breast, skin, and head and neck. Research with dogs has also contributed to scientists' understanding of cardiovascular diseases. Cardiac pacemakers and stents, developed with the help of dogs, are also placed in pet dogs with heart disease. Some of the most prescribed drugs and medical devices have been developed with dogs and also benefit dogs, including lisinopril, glucometers and blood pressure monitors. And, dogs were instrumental test subjects in the early experiments that led to the discovery of insulin. Not only did this work save the lives of countless diabetic humans over the past century, but it also benefited diabetic dogs. Scientists and laboratory animal veterinarians are committed to advancing knowledge and improving both human and animal health while upholding the highest standards of care. These professionals replace dogs with other research models whenever scientifically possible. But in many areas of research, including comparative oncology, using dogs is necessary. When considering the ethical implications of conducting research with dogs, we should also consider the ethical implications of depriving millions of animal and human patients of treatments if a moratorium on canine research is put in place. Instead of painting a target on the backs of scientists who work with dogs to advance knowledge and treatments, we should understand and respect the necessity of their work for the sake of human and animal health. Matthew R. Bailey, Washington The writer is president of the Foundation for Biomedical Research. Jane Goodall and Marc Bekoff painted a deeply troubling picture of animal testing. But the truth is more balanced: Goodall and Bekoff omitted critical context about why animal research occurs and how these animals are cared for. The American public benefits from animal testing as many researchers seek treatments for diseases that affect both humans and pets. The decision to use dogs is not made lightly, and they are used only when no other species can answer the proposed research questions. Though most dogs that are used as research subjects must ultimately be humanely euthanized, their contributions allow scientists to gather critical data that leads to lifesaving treatments and cures. Honoring these animals means ensuring their time in research is as comfortable as possible and recognizing the lasting impact they have on future generations. The public deserves a more realistic outlook on the challenges we face in medicine and the resources we need to address them in the safest, most effective and timeliest ways possible. The assertion that dogs are 'routinely mutilated' is not true. Studies must be necessary, ethical and conducted with the highest standards of care. Ethics committees composed of veterinarians and nonscientists assess the scientific justifications for using animals while governing the veterinary oversight needed to uphold their health and care. This includes using analgesics, anesthetics and tranquilizers whenever possible to minimize and alleviate discomfort. Researchers are committed to considering alternatives to animals such as computer modeling, cell cultures and artificial intelligence. Welfare violations of any kind are taken seriously and warrant thorough review. But when these deplorable incidents occur, they do not represent the practices and beliefs of the broader biomedical research community, which remains committed to the people and animals in its care. Sweeping decisions to eliminate certain species in research would be irresponsible and shortsighted, as this work not only improves animal health but also holds promise for millions of Americans. Discussions about animal research should be grounded in a complete understanding of both ethical considerations and the medical advances it allows. We owe it to the public — and to the animals — to ensure the conversation is driven by facts and realistic expectations rather than emotion and examples devoid of context. Eliminating studies on dogs might seem like a noble goal, but we must ask: What is the cost? Naomi Charalambakis, Washington The writer is a neuroscientist and is director of communications and science policy at Americans for Medical Progress. I was so grateful as I read Jane Goodall and Marc Bekoff's essay detailing the cruel treatment of dogs in some U.S. laboratories. Most of us feel immense compassion for dogs, but let's also remember that other animals used in testing are just as sentient. Many animals, however, are still used for trivial purposes, including testing household products such as oven cleaner. Let's end product testing on animals now, and work to phase out medical testing on animals in favor of more ethical methods. Karen Dawn, Santa Barbara, California The writer is founder and director of DawnWatch, an animal advocacy organization. Sen. Todd Young (R-Indiana) and Matt Pottinger, in their March 25 Tuesday Opinion essay, 'R&D funding isn't a gift to academia,' were right to call for renewed federal investment in science and technology. Public funding for research and development is not a charitable gesture. It's the beating heart of U.S. technological leadership. History proves this. The internet wasn't invented in a garage; it was born out of the Defense Department's ARPANET, a Cold War-era federal project designed to secure military communications. As Mariana Mazzucato wrote in her book 'The Entrepreneurial State,' nearly every component of the iPhone, including GPS, touch-screen and voice-recognition software, was made possible by decades of public investment. Yet we've allowed a dangerous myth to take root: that only private markets innovate. In fact, private capital rarely steps in until the government has de-risked basic science. As Annie Jacobsen documented in her book 'The Pentagon's Brain,' the Defense Advanced Research Projects Agency invested in ideas far too speculative for the private sector. Today, as China escalates its own R&D investment, the stakes are no longer just economic. This is about national security. Science and innovation aren't luxuries; they're important tools in our arsenal. If we want to stay ahead, we must fund bold, mission-driven science and ensure that the American people, who foot the bill, share in the rewards. That means not just commercialization but also reinvestment in public goods. Let's stop pretending R&D is a handout. It's a strategy, and it's one we pioneered. Joseph Frusci, New York What happened to President Donald Trump's visionary commitment to ending the HIV/AIDS epidemic? Hundreds of the foremost HIV scholars around the country recently received letters terminating their research grants funded by the National Institutes of Health. And NIH funding for the Adolescent Medicine Trials Network, which since 2001 has focused on preventing HIV among adolescents and saving children living with HIV, was also abruptly terminated. Many of the termination letters noted that 'so-called diversity, equity, and inclusion ('DEI') studies are often used to support unlawful discrimination on the basis of race and other protected characteristics, which harms the health of Americans. Therefore, it is the policy of NIH not to prioritize such research programs.' The Trump administration is also considering closing the Division of HIV Prevention at the Centers for Disease Control and Prevention, which funds more than $1 billion in lifesaving programs around the country. Thousands of federal public health workers recently had their employment abruptly terminated or reassigned, many of them in the HIV field. HHS also announced its intention to remove all current members of the Presidential Advisory Council on HIV/AIDS, which provides the presidents' policy counsel about HIV issues. This is all a major reversal from Trump's 2019 State of the Union address, in which he announced a goal of ending the HIV/AIDS epidemic by 2030. The programs that followed Trump's strategy worked. More people have access to HIV prevention and treatment than at any time in history. HIV infections are down overall, with approximately 32,000 new HIV infections in 2022, which is a 12 percent decline from 2018. Trump's plan compelled government agencies to coordinate with churches, nonprofit organizations and researchers to ensure that everyone has access to the HIV prevention and care services they need. Thanks to NIH research investments, most HIV cases can now be both prevented and treated with as little as one pill a day. One big public health challenge is delivering lifesaving medications to the people who need them most. This is easier said than done and requires important research in real-world clinical settings. Our approach to engaging and retaining Black men in HIV prevention services has proved highly effective in pilot studies and was cited as an evidence-based best-practice intervention by the CDC in 2023. However, our larger study exploring how to scale that successful program to clinics across the United States, including in the Deep South, was terminated last month. Many people need help accessing lifesaving medications, transportation to their appointments, and special support to pay for and adhere to their HIV medications. Thanks to Trump's 2019 plan to end the HIV epidemic, for the first time, most people who needed HIV medications could get them at no or low cost, even in rural communities. Red states benefited handsomely from this initiative, which pumped millions of dollars of resources into rural communities with high HIV rates, few physicians and few clinics. Our own research with African American clergy in the South demonstrated that this strategy really works. Mr. President, you had an incredible plan to end the HIV epidemic. It saved lives. Please bring it back. Amy Nunn and Philip A. Chan, Providence, Rhode Island Amy Nunn is a professor of public health at Brown University and is chief executive officer of the Rhode Island Public Health Institute. Philip A. Chan is an associate professor of medicine and public health at Brown, chief medical officer of the Rhode Island Public Health Institute and a member of the Presidential Advisory Council on HIV/AIDS. Do you have a grievance with our grammar? Are you irked with our omissions? Do you crave different coverage? Or do you just wonder how The Post does our work? You're in luck. On April 23 at 1 p.m., the letters team will be answering your questions in a live chat, so submit them now for the best chance of a detailed answer:
Miami Herald
03-04-2025
- Miami Herald
Pregnant creature with venomous bite found in Peru mountains. It's a new species
On a mountain ridge in Peru, a 1-foot-long creature with a venomous bite sat in the afternoon sun. Its 'distinct' yellow-ringed eyes scanned its surroundings, but it wasn't the only one looking around. Passing scientists noticed the 'smooth' animal; they didn't know it at the time, but they'd just discovered a new species. Researchers visited several sites throughout Peru between 2000 and 2012 in search of snakes and sent their specimens to a museum. Years later, the team realized it might have misidentified some animals, according to a study published April 2 in the peer-reviewed journal Taxonomy. To sort it out, researchers took a closer look at the museum specimens, tested their DNA, compared photos of the live snakes and reread their notes from the field, the study said. Slowly, a pattern began to emerge; some of the snakes were subtly but consistently different from all known species. Researchers realized they'd discovered a new species: Tachymenoides goodallae, or Goodall's slender snake. Goodall's slender snakes are 'smooth,' reaching up to about 22 inches in length, the study said. They have brown eyes with a 'distinct yellowish-tan ringlet.' Photos show the coloring of the new species. Seen from above, the snakes vary from 'olive brown to pale grayish brown with scattered black and cream flecks.' Seen from below, their coloring is even more 'highly variable,' with bellies ranging from 'uniformly black' to tan or gray. Researchers said they named the new species after Jane Goodall 'for her scientific accomplishments and worldwide conservation activism, which inspire and encourage people to protect biodiversity … We hope that our dedication to Dr. Jane Goodall helps to create awareness for the protection of snakes, many of which are killed out of fear.' Goodall's slender snakes live in mountain forests between elevations of about 7,100 to 10,000 feet, the study said. They are 'venomous but harmless to humans.' One male snake was 'found in the afternoon sun, basking,' researchers said. Two female snakes were found pregnant with five or six 'yolky eggs.' Goodall's slender snakes have a 'large' distribution from central to southern Peru, the study said. The new species was identified by its eyes, teeth, coloring, scale pattern, genitalia and other subtle physical features, the study said. Researchers did not provide a DNA analysis of the new species. The research team included Edgar Lehr, Mikael Lundberg, Juan Carlos Cusi, Jack Sites Jr., Claudia Torres and César Aguilar-Puntriano.
